Novo Nordisk is a Danish multinational healthcare company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries. It is the world's largest producer of insulin and has a leading position in the treatment of diabetes. The company also develops and markets treatments for obesity, growth hormone deficiency, and other chronic diseases.

Novo Nordisk was founded in 1923 by August Krogh and Hans Christian Hagedorn. The company's first product was a form of insulin that was easier to use than the previous versions. Novo Nordisk has since developed a wide range of diabetes treatments, including insulin pens, continuous glucose monitors, and artificial pancreas systems.

In 2021, Novo Nordisk had revenue of $81.2 billion and employed 47,000 people worldwide. The company is listed on the Nasdaq Copenhagen stock exchange and is a constituent of the Euro Stoxx 50 index.

Novo Nordisk is committed to driving change to defeat diabetes and other serious chronic diseases. The company invests heavily in research and development, and it has a strong track record of innovation. Novo Nordisk is also committed to making its products accessible to people around the world, and it works to ensure that people with diabetes have access to the care they need.